Peter Rossing

Medicine · Health Sciences

120h-index76.6kcitations1.4kworks12.62yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(403), Chronic Kidney Disease and Diabetes(285), Diabetes Management and Research(214), Blood Pressure and Hypertension Studies(211), Hormonal Regulation and Hypertension(178)

Publications1.3k total

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Journal of Cachexia Sarcopenia and Muscle·2026Open Access
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD
Kidney International Reports·2025Open Access
Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 Diabetes
Journal of the American College of Cardiology·2025
Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease
International Journal of Molecular Sciences·2025Open Access
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both
Journal of the American Society of Nephrology·2025· 1 citedOpen Access
Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function
Journal of Diabetes and its Complications·2025
Abstract 4369612: Finerenone Reduces Loop Diuretic Requirement in Patients with Type 2 Diabetes and CKD: Participant-Level Pooled Analysis of FIDELIO-DKD and FIGARO-DKD
Circulation·2025
Abstract 4369231: Timing of Cardiovascular and Kidney Benefits with Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes
Circulation·2025
Abstract 4369294: Estimated Lifetime Benefits of Finerenone on Cardiorenal Morbidity and Mortality in Patients with Type 2 Diabetes and Chronic Kidney Disease
Circulation·2025
Abstract 4366042: The HFpEF-ABA Algorithm and Finerenone in Chronic Kidney Disease with Type 2 Diabetes: A FINE-HEART Analysis
Circulation·2025
Long-term risk of major adverse cardiovascular events in individuals with type 1 diabetes, albuminuria, and cardiac impairment
European Heart Journal·2025
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
New England Journal of Medicine·2025
Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease
NEJM Evidence·2025· 2 cited
Exome-Wide Analysis Identifies a Rare EXD3 Missense Variant Associated With Diabetic Kidney Disease
Kidney International Reports·2025Open Access
Response to the letter to the editor entitled “Semaglutide and kidney function: direct kidney protection or an artifact?”
Kidney International·2025
Joslin Kidney Panel of Circulating Proteins
Clinical Journal of the American Society of Nephrology·2025· 1 citedOpen Access
The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Kidney International·2025· 1 citedOpen Access
Impact of Zibotentan and Dapagliflozin Combination Therapy on Lipid Biomarkers in Individuals with CKD
Journal of the American Society of Nephrology·2025
Effect of Semaglutide on Kidney Outcomes: Pooled Analysis of the SELECT, FLOW, and SOUL Trials
Journal of the American Society of Nephrology·2025
#1817 An application of urinary peptidomics and <i>in silico</i> methods to guide multifactorial intervention in chronic kidney disease
Nephrology Dialysis Transplantation·2025
page 1 of 67Next →

Frequent Co-authors

Lise Tarnow(10), Hiddo J.L. Heerspink(8), George L. Bakris(8), Kamlesh Khunti(7), John B. Buse(7), Katherine R. Tuttle(7), Ian H. de Boer(7), Melanie J. Davies(6), Chantal Mathieu(6), Geltrude Mingrone(6), Απόστολος Τσάπας(6), Hans‐Henrik Parving(6), David C. Wheeler(5), Victor Aboyans(5), Frederik Persson(5), Sylvia E. Rosas(5), Sophia Zoungas(5), Tami Sadusky(5), Peter Hovind(5), Harald Mischak(5)